Floatz logo

Therapeutic Asset Ratings

615 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
DALPICICLIB ISETIONATE
Metastatic Cancer
Fudan UniversityP2CCC (51)
Donafenib
Malignant Pancreatic Neoplasm
Fudan UniversityP2CCC (51)
Endostar
Melanoma
Fudan UniversityP2CCC (51)
Ensartinib
Metastatic Malignant Neoplasm In The Brain
Fudan UniversityP2CCC (51)
ETOPOSIDE
Intrahepatic Cholangiocarcinoma (Icc)
Fudan UniversityP2CCC (51)
FLUOROURACILUM
Relapse
Fudan UniversityP2CCC (51)
FUROSEMIDE
Metastatic Prostate Cancer
Fudan UniversityP2CCC (51)
Ifosfamide
Rhabdomyosarcoma
Fudan UniversityP2CCC (51)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Colorectal Cancer
Fudan UniversityP2CCC (51)
Iparomlimab
Intrahepatic Cholangiocarcinoma (Icc)
Fudan UniversityP2CCC (51)
Irinotecan
Radiotherapy
Fudan UniversityP2CCC (51)
Irinotecan
Relapse
Fudan UniversityP2CCC (51)
Ivocizumab
Kidney Cancer
Fudan UniversityP2CCC (51)
Ivocizumab
Rhabdomyosarcoma
Fudan UniversityP2CCC (51)
Ivocizumab
Sarcoma
Fudan UniversityP2CCC (51)
Ivocizumab
Urothelial Carcinoma
Fudan UniversityP2CCC (51)
Narlumosbart
Immunotherapy
Fudan UniversityP2CCC (51)
Plavix
Metastatic Prostate Cancer
Fudan UniversityP2CCC (51)
Rivoceranib
Colon Carcinoma
Fudan UniversityP2CCC (51)
Rivoceranib
Rectal Cancer
Fudan UniversityP2CCC (51)
shr0302
Breast Cancer
Fudan UniversityP2CCC (51)
shr0302
Triple-Negative Breast Carcinoma
Fudan UniversityP2CCC (51)
Shr-A1921
Breast Cancer
Fudan UniversityP2CCC (51)
Shr-A2009
Triple-Negative Breast Carcinoma
Fudan UniversityP2CCC (51)
Shr-A2102
Breast Cancer
Fudan UniversityP2CCC (51)
Showing 426 to 450 of 615 assets
PreviousPage 18 of 25Next